Peter Greenleaf, a newly appointed director at Altimmune, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 4, 2026, disclosing no securities beneficially owned as of the event date of November 2, 2026.

Key Highlights

  • Reporting person: Peter Greenleaf, identified in the filing as a Director of Altimmune, Inc. (NASDAQ:ALT).
  • Event date: The date of the event requiring the statement is listed as November 2, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both the non-derivative and derivative securities tables.
  • Filing date: The form was signed and filed on November 4, 2026, by Gregory Weaver as Attorney-in-Fact.
  • Individual filing: The form was filed by one reporting person, not a group.

Greenleaf Reports Zero Holdings Upon Joining Altimmune Board

Peter Greenleaf filed a Form 3 with the U.S. Securities and Exchange Commission on November 4, 2026, as required under Section 16(a) of the Securities Exchange Act of 1934. The filing covers his initial statement of beneficial ownership in connection with his role as a Director of Altimmune, Inc., traded on NASDAQ:ALT. The triggering event date is listed as November 2, 2026, according to the filing.

Both Table I (Non-Derivative Securities) and Table II (Derivative Securities) in the filing are empty. The form includes the explicit notation: "No securities are beneficially owned." This means Greenleaf reported holding no shares, options, warrants, or other derivative instruments tied to Altimmune at the time of the filing event.

The form was signed on November 4, 2026, by Gregory Weaver in his capacity as Attorney-in-Fact for Greenleaf. Greenleaf's address of record listed in the filing is 350 Mount Kemble Avenue, Suite 1001, Morristown, New Jersey 07960. No amendment date was indicated, confirming this is an original filing rather than a revision of a prior statement.

What Was Disclosed

Altimmune director Peter Greenleaf submitted an initial beneficial ownership statement reporting no direct or indirect holdings of Altimmune securities, either non-derivative or derivative, as of the November 2, 2026 event date.